Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16248 | 0.74 | MAPK1 (0.47) | DAOCRBNMAPK1HPGD | |
| SCHEMBL2986044 | 0.73 | DAO (0.46) | DAOCRBNMAPK1CYP3A4PMP22 | |
| SCHEMBL35345 | 0.73 | TDP1 (0.57) | DAOCRBNTDP1KMT2ASMN1; SMN2 | |
| SCHEMBL4379053 | 0.73 | DAO (0.43) | DAOCRBNMAPK1CYP3A4PMP22 | |
| SCHEMBL4379055 | 0.73 | DAO (0.43) | DAOCRBNMAPK1CYP3A4PMP22 | |
| SCHEMBL23224166 | 0.73 | DAO (0.43) | DAOCRBNMAPK1CYP3A4PMP22 | |
| SCHEMBL6420314 | 0.73 | MAPK1 (0.46) | DAOCRBNMAPK1HPGD | |
| SCHEMBL20215653 | 0.71 | DAO (0.46) | DAOCRBNMAPK1CYP3A4PMP22 | |
| SCHEMBL35260 | 0.71 | SMN1; SMN2 (0.42) | DAOCRBNMAPK1CYP3A4PMP22 | |
| SCHEMBL11144152 | 0.71 | TDP1 (0.55) | DAOCRBNTDP1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012077800-A1 | NOVEL NUCLEOSIDE ANALOG AND UTILIZATION THEREOF | 国立大学法人九州大学 (JP) | 2012-06-14 | — | — | WO | disclosed |
| US-20110059014-A1 | COMPOUNDS AND METHODS OF MAKING COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059014-A1 | COMPOUNDS AND METHODS OF MAKING COMPOUNDS | MCL1, TOP2B, TOP1 | DAO 3262/4885CRBN 1469/4885MAPK1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.